Literature DB >> 25678928

P-glycoprotein A Gene Expression in Glucantime-Resistant and Sensitive Leishmania major (MRHO/IR/75/ER).

Simindokht Soleimanifard1, Reza Arjmand2, Sedighe Saberi1, Ali Khamesipour3, Mohammad Kazemi4, Mansoor Salehi4, Mojtaba Akbari5, SeyedHossein Hejazi6.   

Abstract

BACKGROUND: Leishmaniasis is a parasitic disease caused by different species of Leishmania parasites with a wide range of clinical manifestations. Antimonial compounds such as meglumine antimoniate (glucantime) are the first line drugs for the treatment of leishmaniasis. However, according to reports of the drug resistance of parasites, the efficacy of antimonial compounds is low. The ATP-binding cassette (ABC) proteins are present in all organisms and mediate the transport of vital elements through biological membranes. One of the important mechanisms of resistance in Leishmania parasites is the overexpression of ABC efflux pumps. P-glycoprotein A (pgpA) is a related gene for ABC transporter in Leishmania species. The aim of this study was to compare the pgpA expression in laboratory-induced resistant L. major (MRHO/IR/75/ER) and sensitive parasites.
METHODS: RNA extraction of promastigotes of sensitive and resistant clones was performed and total RNA was reverse transcribed. The real-time quantitative polymerase chain reaction (PCR) was used to assess RNA expression profiles and the expression levels were calculated using 2(-ΔCt) method.
RESULTS: The mean expression level of pgpA mRNA was 2.70 ± 0.51 in in sensitive Leishmania clone and 6.08 ± 1.50 in resistant Leishmania clone (P = 0.021).
CONCLUSION: The expression of pgpA gene in resistant strains of L. major was almost fivefold higher than those in susceptible strains. Therefore, this can be used in field isolates, i.e. overexpression of the gene can prove resistance in wild type field isolates.

Entities:  

Keywords:  Leishmania major; P-glycoprotein A; Real-time RT-PCR; glucantime

Year:  2014        PMID: 25678928      PMCID: PMC4316575     

Source DB:  PubMed          Journal:  Iran J Parasitol        ISSN: 1735-7020            Impact factor:   1.012


Introduction

Leishmaniasis is a range of diseases caused by different obligate intracellular parasites of Leishmania species and transmitted by the bite of infected sand flies (1). While cutaneous leishmaniasis (CL) due to L. tropica is known as anthroponotic CL (ACL) or urban form of the disease, the zoonotic CL (ZCL), which is caused by L. major, is endemic in many rural areas of Iran (1). Although antimonial compounds such as meglumine antimoniate (glucantime) have been the first line drugs for the treatment of leishmaniasis, they are now proved not to have adequate efficacy and to cause resistance in long-term use (2-4). However, the main reasons for such problems have not been well explained. On the other hand, while it is difficult to justify the development of natural resistance of wild L. major in the field, laboratory-induced resistance can be used to assess ATP-binding cassette (ABC) proteins (5), which are present in all organisms as a frequent mechanism by which Leishmania responds to drug selection (6, 7). Most of these proteins mediate transport across biological membranes (5). Over-expression of ABC efflux pumps may be an important way to produce resistant Leishmania parasites (8). One of the genes for an ABC transporter in Leishmania is a P-glycoprotein A (pgpA) (9) which is commonly amplified in metal-resistance in Leishmania (9). The amount of trypanothione (TSH), a glutathione-spermidine conjugate (10), is increased in several Leishmania species which are resistant to metal. TSH is the main reduced thiol in Leishmania and the metal-TSH conjugate might be sequestered to an intracellular compartment using pgpA. The metal-TSH conjugate may leave cells by exocytosis generally through the flagellar pocket (11, 12). In this study, pgpA expression was compared between laboratory-induced glucantimeresistant L. major and unchanged susceptible reference parasite. In our lab glucantime resistant model of L. major strain was transformed from natural intact line with the aim of comparison pgpA gene expression in wild type isolates from patients with no response to chemotherapy with glucantime in the future studies. We hypothesized that resistant and susceptible parasites would have different pgpA gene expressions. The results of this study would promote our understanding of not only mechanisms through which Leishmania evades the killing effects of drugs but also different pathways used by Leishmania to neutralize the therapeutic effects of chemical formulations such as glucantime.

Materials and Methods

Parasite and in-vitro culture

L. major promastigotes (MRHO/IR/75/ER) were used for the current study. In order to avoid using over-passaged parasites and to maintain virulence, 0.1 ml phosphate buffered saline (PBS) containing 2 × 106 L. major promastigotes was inoculated subcutaneously in the base of the tail of BALB/c mice. Threefour weeks after the injection, the lesions appeared and the infected mice were autopsied. The animals’ spleens were removed, homogenized under sterile conditions, and transferred to modified NNN medium. Mass production of promastigotes was performed via subpassaging of the isolates from the NNN medium in RPMI 1640 medium. Drug sensitivity of the proliferated isolates was proved using the half maximal inhibitory concentration (IC50) method since 50% of the promastigotes died in the presence of glucantime concentrations of 10 μg/ml (4).

Induction of resistance in cultured promastigotes

L. major parasites were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS) at 23-25°C. In order to induce resistance, the parasites were then pulsed by gradually increasing meglumine antimoniate concentration from 1 mg/ml to 5, 10, 15, 30, 60, and finally 120 mg/ml. The upper limit of 120 mg/ml was selected based on the toxicity for the promastigotes. Each 5-ml ampoule of glucantime contained 1.5 g meglumine antimoniate corresponding to 0.405 g of pentavalent antimony (13).

RNA isolation

Total RNA was extracted using RNeasy Mini Kit (QIAGEN, Germany) according to the manufacturer’s protocol. Centrifugation was then employed to pack 5 × 106 alive promastigotes from the media containing sensitive and resistant parasites. The harvested promastigotes were washed three times and RNA extraction was performed. The samples were treated with a DNA-free kit (Fermentas, USA) to remove possible contaminated genomic DNA. RNA concentration was determined using absorbance at 260 nm in a spectrophotometer (NanoDrop, USA).

cDNA synthesis and Real-time quantitative PCR

Total RNA was reverse transcribed using RevertAid First Strand cDNA Synthesis Kit (Fermentas, USA) with a random hexamer and according to the manufacturer’s instructions. Briefly, 1 μl of random hexamer was added to 11 μl of extracted RNA and incubated at 65°C for five minutes. After adding 4 μl of reaction buffer, 1 μl of RiboLock RNase Inhibitor (Life Science Research, USA), 2 μl of Revert Aid, and 1 μl (200 U/μl ) of transcriptase, a thermal cycler (Bio-Rad, USA) was used to incubate the samples at 42°C for 60 minutes and then at 70°C for five minutes. Subsequently, 1.5 μl of the resulting cDNA was used as the template and added to 18.5 μl of SYBR Green quantitative PCR reactions (Sigma-Aldrich, USA) and entered into the ABI 1 plus model of real-time PCR for 40 cycles. Forward and reverse primers were designed by the National Center for Biotechnology Information (NCBI) (Table 1).
Table 1

Forward and reverse primers

GeneForward primerReverse PrimerAmplicon size
18s rRNACCAAAGTGTGGAGATCGAAGGGCCGGTAAAGGCCGAATAG187
PGPAGGTCTCATCTCGCTG TCACTACGCTCCACGCTGTTCAT108
PCR amplification consisted of an initial denaturation at 95°C for 10 minutes, followed by 40 cycles of denaturation at 95°C for 15 seconds, and annealing and extension at 60°C for one minute. Melting curve analysis (60°C → 95°C increment at 0.3°C) was used to determine the melting temperature of specific amplification products and primer dimers. These experiments were independently repeated for at least three times. Quantitative real-time RT PCR was performed to quantitatively estimate the RNA expression of sensitive and resistant L. major. Two genes were analyzed: first pgpA involved in metal resistance and 18s rRNA (internal control) for normalization purposes. Following the generation of the standard curve, the PCR efficiency of genes was determined. For real time reverse transcribed PCR data analysis, 2-ΔCt method was used. Data was analyzed using t-tests.

Results

Expression of pgpA mRNA of antimony [Sb (V)] sensitive and resistant mutants was verified as mentioned. The extracted RNA samples were checked with agarose gel electrophoresis. Sharp ribosomal RNA bands of 18s and 28s without smears represented the intact and adequately qualified RNA. Moreover, cDNA was synthesized from 0.495 μg of the extracted RNA. The total extracted RNA concentration was 45 μg/ml and the OD260/280 ratio was 1.9. The mean expression of pgpA mRNA normalized to 18s rRNA endogenous gene was significantly higher in resistant parasites than in sensitive samples (6.08 ± 1.50 vs. 2.70 ± 0.51; P = 0.021) (Figure 1). The efficacy of the primer set and PCR was 95%. In addition, pgpA expression with 2-ΔCt method showed fivefold expression in resistant line when compared to the susceptible line.
Fig. 1

Comparison of different relative pgpA mRNA expression in sensitive and resistant Leishmania major promastigotes

Discussion

Pentavalent antimonials have been the sole and first choice treatment of CL in the past decades. Glucantime concentration and the duration of therapy have recently increased in order to maintain the strong therapeutic effects of treatment (14). However, treatment efficacy is still low and cases of resistance have been reported (2-4, 14). It is strongly suspected that the parasite has acquired mutations to induce resistance to glucantime (15). Thus, it seems necessary to investigate molecular mechanism(s) involved in non-responsiveness of clinical treatment and possibly drug resistance, not only to track drug resistance spread, but also for designing new and efficient drugs for the treatment of refractory leishmaniasis. North Bihar in India is an area of anthroponotic visceral leishmaniasis with increasing cases of drug-resistant leishmaniasis. Several studies have reported that in this area, the disease is poorly responding to treatment with antimony and that 34%-65% of the cases have actually failed to respond to treatment (16). In vitro studies with amastigotes have demonstrated that treatment failure is a result of decreased sensitivity of the parasite to antimony (17). Reports of unresponsiveness to treatment have also come from Iran. A crosssectional research in Mashhad (a north-eastern city of Iran) indicated that 13% of patients did not respond to treatment with glucantime (4). In order to obtain more information about parasite resistance, we compared pgpA gene expression from L. major with laboratory-induced resistance to treatment and homogenous sensitive L. major. Among all pathways for metal resistance, overexpression of energydependent transporters seems to play a major role (18). For instance, pgpA are large membrane proteins that act as ATP-dependent extrusion pumps. They are responsible for effluxing the drug from the parasite or collection that in vesicles and are hence crucial in the protection of parasites from the killing effects of the drug (19). These proteins have been shown to amplify as an extrachromosomal circle (H-circle) in a methotrexate resistant L. tarentolae promastigotes cell line (20). Quantitative RT-Real-time PCR is a highly sensitive technique enabling the amplification and quantification of a specific nucleic acid sequence with detection of the target gene and its expression. In recent years, this method has been widely used to assess the expression of different genes of Leishmania. A typical example is calcineurin which is a protein phosphatase with a critical role in the apoptosis of resistant and sensitive L. infantum isolates from endemic areas of Iran (21). Heather et al. studied two different lines of L. major (the wild type and the pgpA gene transfected L. major). They evaluated antimonial accumulation using electrothermal atomic absorption spectrophotometry and found a fourfold reduction in the accumulation of antimony in resistant pgpA-transfectants (22). In another study to determine the role of genetic variation in resistant phenotypes, Alizadeh et al. assessed samples collected from endemic areas of Iran. The mutation of multidrug resistant (MDR) gene was evaluated with PCR method. They found that 11.1% of the patients showed changes in the MDR gene sequences (20). Genomic variation in sodium stibogluconate resistance has also been reported in patients with anthroponotic CL (13). The overexpression of pgpA has been suggested as a major reason of drug resistant in Indian visceral leishmaniasis due to L. donovani (23). Similarly, the overexpression of pgpA has been found in resistant axenic amastigotes of L. infantum. The transfection of this gene shows antimonyresistance upon promastigotes and amastigotes of L. infantum (24).

Conclusion

According to the results of the present study, the expression of pgpA gene in resistant strains of L. major was almost fivefold higher than those in susceptible strains. Therefore, the rate of pgpA expression can be used as an indication in field isolates, i.e. overexpression of the gene can prove resistance in wild type field isolates.
  23 in total

1.  Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major.

Authors:  Babak Shazad; Babak Abbaszadeh; Ali Khamesipour
Journal:  Eur J Dermatol       Date:  2005 Mar-Apr       Impact factor: 3.328

Review 2.  ABC proteins of Leishmania.

Authors:  D Légaré; S Cayer; A K Singh; D Richard; B Papadopoulou; M Ouellette
Journal:  J Bioenerg Biomembr       Date:  2001-12       Impact factor: 2.945

3.  Efflux systems and increased trypanothione levels in arsenite-resistant Leishmania.

Authors:  D Légaré; B Papadopoulou; G Roy; R Mukhopadhyay; A Haimeur; S Dey; K Grondin; C Brochu; B P Rosen; M Ouellette
Journal:  Exp Parasitol       Date:  1997-11       Impact factor: 2.011

4.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

Authors:  R Lira; S Sundar; A Makharia; R Kenney; A Gam; E Saraiva; D Sacks
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

5.  Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.

Authors:  B Pourmohammadi; M H Motazedian; F Handjani; G H R Hatam; S Habibi; B Sarkari
Journal:  Southeast Asian J Trop Med Public Health       Date:  2011-05       Impact factor: 0.267

6.  The PGPA gene of Leishmania major mediates antimony (SbIII) resistance by decreasing influx and not by increasing efflux.

Authors:  H L Callahan; W L Roberts; P M Rainey; S M Beverley
Journal:  Mol Biochem Parasitol       Date:  1994-11       Impact factor: 1.759

7.  Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania.

Authors:  R Mukhopadhyay; S Dey; N Xu; D Gage; J Lightbody; M Ouellette; B P Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

8.  Role of aquaglyceroporin (AQP1) gene and drug uptake in antimony-resistant clinical isolates of Leishmania donovani.

Authors:  Mahendra Maharjan; Sushma Singh; Mitali Chatterjee; Rentala Madhubala
Journal:  Am J Trop Med Hyg       Date:  2008-07       Impact factor: 2.345

9.  Use of antimony in the treatment of leishmaniasis: current status and future directions.

Authors:  Arun Kumar Haldar; Pradip Sen; Syamal Roy
Journal:  Mol Biol Int       Date:  2011-06-08

10.  Detection of drug resistance gene in cutaneous leishmaniasis by PCR in some endemic areas of iran.

Authors:  R Alizadeh; H Hooshyar; M Bandehpor; M Arbabi; F Kazemi; A Talari; B Kazemi
Journal:  Iran Red Crescent Med J       Date:  2011-12-01       Impact factor: 0.611

View more
  1 in total

Review 1.  Global distribution of treatment resistance gene markers for leishmaniasis.

Authors:  Samira Salari; Mehdi Bamorovat; Iraj Sharifi; Pooya Ghasemi Nejad Almani
Journal:  J Clin Lab Anal       Date:  2022-07-09       Impact factor: 3.124

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.